Global CNS pharmaceuticals market forecast to grow to $63bn by 2010 Thursday 14 June 2007 PDF Print The global market for pharmaceuticals treating Central Nervous System (CNS) disorders is forecast to reach $63bn by 2010, says new report available from ReportBuyer.com, the online destination for business intelligence. Findings in the 125 page CNS Market Trends, 2007 to 2010 - Key Market Forecasts and Growth Opportunities include: - The global CNS market is forecast to expand to US$63.9 billion in 2010 but growth will be limited by mature markets in depression and epilepsy and continued patent expiries for major products. - Of the top 20 products by global CNS sales in 2005, 13 generated annual sales in excess of US$1 billion. - 5 of the top 10 CNS companies AstraZeneca, Forest, GSK, Sanofi-Aventis and Wyeth are forecast to grow their CNS sales over the next five years. J&J, Novartis and Abbott are forecast to suffer declining CNS sales over the next five years. -A total of 15 pharmaceutical companies were identified as having generated CNS sales in excess of US$1 billion in 2005. - Topamax was the leading epilepsy drug in 2005 with sales of US$1.7 billion. Other blockbuster epilepsy drugs include the second generation anti-convulsant, Lamictal and traditional anti-convulsant, Depakote. - The global market for CNS-related pharmaceuticals was dominated by the anti-depressant drug class with a market share of more than 30% The report provides key information for those with an interest in the market for treatments of Central Nervous System disorders. - Sales forecast for top ten companies providing CNS treatment medicines. - Analysis of leading CNS products likely to loose patent protection in the next ten years. - Sales forecasts to 2010 for the top ten CNS medicines and forecasts by drug class. - Overview of disease incidence, areas of growth and breakdown of disease burden and mortality. - Breakdown of the major market trends and business opportunities. - In-depth coverage of the following companies' CNS market presence: Abbott, AstraZeneca, Eli Lilly, Forest, GlaxoSmithKline, Johnson & Johnson, Novartis, Pfizer, Sanofi-Aventis, Wyeth. Content of the report: Executive Summary Chapter 1. Overview of Global CNS Market Chapter 2. Key CNS Disease Markets Chapter 3. Key CNS Drug Classes Chapter 4. Key CNS Products Chapter 5. Key Companies Involved in CNS Chapter 6. Key Trends and Opportunities in CNS Appendix Figures Tables CNS Market Trends, 2007 to 2010 - Key Market Forecasts and Growth Opportunities is available in PDF format from Report Buyer. www.reportbuyer.com This press release was distributed by ResponseSource Press Release Wire on behalf of Report Buyer in the following categories: Medical & Pharmaceutical, for more information visit http://pressreleasewire.responsesource.com/about.